secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2026-10-16T20:30:35+00:00
Accession:  0001104659-26-116632
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4.1-flash:cloud@v2

Acurx holders re-elect Luci, Dean as Class II directors; ratify CohnReznick for FY2026
--------------------------------------------------------------------------------

- Annual meeting held Oct 16, 2026; record date Aug 20, 2026 with 5,471,297 shares outstanding; quorum of 2,890,899 shares, or 52.83%.
- David P. Luci re-elected with 1,187,323 votes for and 73,804 withheld; Jack H. Dean with 1,203,310 for and 57,817 withheld.
- Both Class II directors serve three-year terms expiring in 2029; broker non-votes totaled 1,629,772 on the director proposals.
- Stockholders ratified CohnReznick LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2026: 2,877,193 for, 8,473 against, 5,233 abstentions.
- Two proposals were submitted, per the definitive proxy statement filed Sept 1, 2026; no other business reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465926116632/0001104659-26-116632-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465926116632/tm2627481d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-116632

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer